Matthew J. Armstrong

11.2k total citations · 5 hit papers
130 papers, 6.2k citations indexed

About

Matthew J. Armstrong is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Matthew J. Armstrong has authored 130 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Epidemiology, 56 papers in Hepatology and 39 papers in Surgery. Recurrent topics in Matthew J. Armstrong's work include Liver Disease Diagnosis and Treatment (69 papers), Liver Disease and Transplantation (45 papers) and Nutrition and Health in Aging (22 papers). Matthew J. Armstrong is often cited by papers focused on Liver Disease Diagnosis and Treatment (69 papers), Liver Disease and Transplantation (45 papers) and Nutrition and Health in Aging (22 papers). Matthew J. Armstrong collaborates with scholars based in United Kingdom, United States and Germany. Matthew J. Armstrong's co-authors include Philip N. Newsome, Jeremy Tomlinson, Stephen Gough, Jonathan Hazlehurst, Richard Parker, Diana Hull, Darren Barton, Kathy Guo, Stefan G. Hübscher and Ali Canbay and has published in prestigious journals such as The Lancet, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Matthew J. Armstrong

125 papers receiving 6.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

2015 1.6k citations Matthew J. Armstrong, Piers Gaunt et al. profile →
Extrahepatic complications of nonalcoholic fatty liver disease

2013 457 citations Matthew J. Armstrong et al. Hepatology profile →
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

2015 351 citations Matthew J. Armstrong, Diana Hull et al. Journal of Hepatology profile →
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

2023 282 citations Matthew J. Armstrong, Arun J. Sanyal et al. profile →
Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension

2020 179 citations Dhiraj Tripathi, Adrian J. Stanley et al. Gut profile →

Peers

Countries citing papers authored by Matthew J. Armstrong

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Armstrong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Armstrong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Armstrong more than expected).

Fields of papers citing papers by Matthew J. Armstrong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Armstrong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Armstrong. The network helps show where Matthew J. Armstrong may publish in the future.

Co-authorship network of co-authors of Matthew J. Armstrong

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Armstrong. A scholar is included among the top collaborators of Matthew J. Armstrong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Armstrong. Matthew J. Armstrong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A home-based exercise programme attenuates fatigue in primary biliary cholangitis: Results from the EXCITED clinical trial 2024 ·JHEP Reports ·(unknown), Felicity Williams, (unknown), Jennifer Hayden, Matthew J. Armstrong, Palak Trivedi	0
2	Study protocol for a Randomised controlled trial of EArly transjugular intrahepatiC porTosystemic stent–shunt in Acute Variceal Bleeding (REACT-AVB trial) 2024 ·BMJ Open Gastroenterology ·Dhiraj Tripathi, David Patch, Homoyon Mehrzad, Dominic Yu, Richard Aspinall, Matthew J. Armstrong, Adrian J. Stanley, Hamish Ireland, Simon Travis, Peter Hayes, (unknown), (unknown), (unknown), Gemma Slinn, Sue Jowett, Catherine A Moakes, (unknown), Elizabeth Brettell, (unknown)	1
3	Improved health‐related quality of life with semaglutide in people with non‐alcoholic steatohepatitis: A randomised trial 2023 ·Alimentary Pharmacology & Therapeutics ·Manuel Romero‐Gómez, Matthew J. Armstrong, (unknown), (unknown), Steen Ladelund, Anne‐Sophie Sejling, (unknown), Arun J. Sanyal	13
4	Topographical Distribution of Neuroanatomical Abnormalities Following COVID-19 Invasion 2023 ·Clinical Neuroradiology ·(unknown), (unknown), (unknown), Matthew J. Armstrong, (unknown), Deniz Çetinkaya, Hana Burianová, Theophilus N. Akudjedu	4
5	Outcomes of incoming and outgoing second opinions from a UK liver transplant centre 2022 ·BMJ Open Gastroenterology ·Alessandro Parente, (unknown), Sara Mahgoub, Sean Michael Morris, Kerry Webb, James Neuberger, Matthew J. Armstrong, Neil Rajoriya	1
6	P048 Geographic variability in rates of intensive care unit admission in patients with chronic liver disease and critical COVID-19: International registry data 2021 ·Thomas Marjot, Andrew M. Moon, Matthew J. Armstrong, Ignacio García‐Juárez, Anand V. Kulkarni, Steven Masson, Nneka N. Ufere, David T. Wong, (unknown), (unknown), A. Sidney Barritt, Eleanor Barnes, Gwilym J. Webb	1
7	A machine learning approach to brain epigenetic analysis reveals kinases associated with Alzheimer’s disease 2021 ·Nature Communications ·Yanting Huang, Xiaobo Sun, (unknown), Shaojun Yu, Chloe Robins, Matthew J. Armstrong, Ronghua Li, Zhen Mei, Xiaochuan Shi, Ekaterina S. Gerasimov, Philip L. De Jager, David A. Bennett, Aliza P. Wingo, Peng Jin, Thomas S. Wingo, Zhaohui Qin	38
8	SARS-CoV-2 infection in patients with autoimmune hepatitis 2021 ·Journal of Hepatology ·Thomas Marjot, Gustav Buescher, Marcial Sebode, Eleanor Barnes, A. Sidney Barritt, Matthew J. Armstrong, (unknown), James Kennedy, Carolyn Mercer, Ann‐Kathrin Ozga, Christian Casar, Christoph Schramm, Andrew M. Moon, Gwilym J. Webb, Ansgar W. Lohse	76
9	OTH-1 SARS-CoV-2 Infection in patients with autoimmune hepatitis 2021 ·Thomas Marjot, Gustav Buescher, Marcial Sebode, Eleanor Barnes, A. Sidney Barritt, Matthew J. Armstrong, (unknown), James C. Kennedy, Carolyn Mercer, Ann‐Kathrin Ozga, Christian Casar, Christoph Schramm, (unknown), Andrew M. Moon, Gwilym J. Webb, Ansgar W. Lohse	1
10	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study 2021 ·BMC Medicine ·Paul McKeigue, David McAllister, David Caldwell, Ciara Gribben, Jen Bishop, Stuart J. McGurnaghan, Matthew J. Armstrong, (unknown), (unknown), Sharon Hutchinson, Chris Robertson, Nazir Lone, Jim McMenamin, David Goldberg, Helen M. Colhoun	14
11	Sarcopenia in cirrhosis: A practical overview 2020 ·Clinical Medicine ·Amritpal Dhaliwal, Matthew J. Armstrong	38
12	Home-based exercise therapy in patients awaiting liver transplantation: protocol for an observational feasibility trial 2018 ·BMJ Open ·Felicity Williams, (unknown), Thomas Faulkner, (unknown), Derek Kyte, (unknown), Jill L. Johnson, Andrew Holt, M. Thamara P. R. Perera, James Ferguson, Matthew J. Armstrong	14
13	Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis 2013 ·Alimentary Pharmacology & Therapeutics ·Richard Parker, Matthew J. Armstrong, Chris Corbett, (unknown), Diarmaid D. Houlihan	73
14	Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial 2013 ·Hepatology ·Matthew J. Armstrong, D. Hull, (unknown), Darren Barton, (unknown), Maryam Nasiri, Laura Gathercole, Jiajun Yu, Piers Gaunt, S Gough, Jeremy Tomlinson, Philip N. Newsome	1
15	Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial 2013 ·BMJ Open ·Matthew J. Armstrong, Darren Barton, Piers Gaunt, Diana Hull, Kathy Guo, Deborah Stocken, Stephen Gough, Jeremy Tomlinson, Rachel M. Brown, Stefan G. Hübscher, Philip N. Newsome, (unknown)	39
16	Scavenger receptor B-I antagonist ITX5061 modulates early HCV kinetics in patients undergoing liver transplantation: results of a phase Ib clinical trial 2013 ·Hepatology ·Ian Rowe, Matthew J. Armstrong, Richard Parker, (unknown), Darren Barton, (unknown), J.F. McKelvy, Flossie Wong‐Staal, David Adams, (unknown), David Mutimer	1
17	Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management 2013 ·QJM ·Matthew J. Armstrong, Jonathan Hazlehurst, Richard Parker, (unknown), Jake P. Mann, (unknown), (unknown), (unknown), Jill L. Johnson, (unknown), Geoffrey Haydon, (unknown), Philip N. Newsome, Jeremy Tomlinson	34
18	PTU-057 Split liver transplant recipients are less likely to require peri-operative renal replacement therapy than full-size liver transplant controls: Abstract PTU-057 Table 1 2012 ·Gut ·(unknown), Matthew J. Armstrong, Chris Corbett, (unknown), (unknown), Francesca Tinti, Bridget Gunson, Darius F. Mirza, Paolo Muiesan, James Ferguson	1
19	High prevalence of advanced NAFLD in type 2 diabetic patients with unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD Program 2010 ·Diabetologia ·Matthew J. Armstrong, A Falahati, (unknown), Wolfgang E. Schmidt, S Gough, Philip N. Newsome	1
20	High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program 2010 ·Diabetes ·Matthew J. Armstrong, A Falahati, Oscar Ö. Braun, Wolfgang E. Schmidt, S Gough, Philip N. Newsome	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact